Rituximab was used as a first-line option in 4 patients (1.9%): 2 anti-MuSK-associated MG cases, 1 with comorbid autoimmune disease and 1 EOMG case with an aggressive course. This evidence concerns the gene MUSK and myasthenia gravis.